R&D | May 14, 2026
Merck to showcase 100+ oncology studies at 2026 ASCO meeting
Highlighting KEYTRUDA & expanding cancer pipeline
Highlighting KEYTRUDA & expanding cancer pipeline
Integrated eCOA technology and rater training aim to reduce variability and strengthen ClinRO outcomes
The presentations underscore the company’s deep expertise in dermatology and immunology
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
These findings follow positive Phase 3 results presented earlier this year
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
These abstracts report on the company's three lead drug candidates, including olverembatinib
Subscribe To Our Newsletter & Stay Updated
